Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Receivables (2023 - 2025)

Fennec Pharmaceuticals' Change in Receivables history spans 3 years, with the latest figure at $3.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 1876.0% year-over-year to $3.5 million, compared with a TTM value of $12.4 million through Dec 2025, up 58.01%, and an annual FY2025 reading of $12.4 million, up 58.01% over the prior year.
  • Change in Receivables for Q4 2025 was $3.5 million at Fennec Pharmaceuticals, up from $3.4 million in the prior quarter.
  • The five-year high for Change in Receivables was $5.3 million in Q1 2025, with the low at $138000.0 in Q1 2023.
  • Average Change in Receivables over 3 years is $2.3 million, with a median of $2.1 million recorded in 2023.
  • Year-over-year, Change in Receivables tumbled 95.92% in 2024 and then surged 1876.0% in 2025.
  • Tracing FENC's Change in Receivables over 3 years: stood at $4.3 million in 2023, then crashed by 95.92% to $175000.0 in 2024, then surged by 1876.0% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Change in Receivables are $3.5 million (Q4 2025), $3.4 million (Q3 2025), and $265000.0 (Q2 2025).